Michigan House Bill HB4837

Michigan 2025-2026 Regular Session

• Introduced: 9/4/25
• Refer: 9/4/25

Caption

Health: pharmaceuticals; ivermectin; allow over-the-counter access. Amends 1978 PA 368 (MCL 333.1101 - 333.25211) by adding secs. 17771 & 17771a.

Impact

The potential impact of HB 4837 on state laws includes a significant shift in how certain pharmaceuticals can be accessed by the public. By permitting pharmacists to sell ivermectin over the counter, this bill could lead to increased availability of the drug, thereby empowering individuals with more direct access to certain medicinal treatments without requiring a doctor's visit. The regulatory framework outlined in the bill encourages pharmacists to ensure safety and quality of the product being sold, thus aiming to protect public health even as accessibility is increased.

Summary

House Bill 4837 proposes amendments to the existing Public Health Code in Michigan, specifically addressing the availability of the drug ivermectin. Under this bill, pharmacists would be authorized to dispense ivermectin without a prescription, allowing more streamlined access to this medication for consumers. Additionally, the bill sets specific criteria for over-the-counter sales, stipulating that ivermectin may only be sold if it is manufactured following good manufacturing practices and if its packaging includes comprehensive dosage instructions, contraindications, and safety information.

Contention

There are notable points of contention surrounding HB 4837. While proponents argue that this legislation can improve access to ivermectin—particularly for those in need of treatments that may not require physician oversight—critics may raise concerns regarding safety and efficacy. The lack of prescription oversight could lead to potential misuse or unsupervised consumption of the drug, prompting discussions about the implications for public health. Stakeholders, including health professionals and advocacy groups, may voice differing opinions on whether empowering pharmacists in this way represents a genuine advancement in healthcare access or a risky deregulation of pharmaceuticals.